Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$56 Mln
Revenue (TTM)
$51 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.2
Industry P/E
--
EV/EBITDA
-0.3
Div. Yield
0 %
Debt to Equity
0.5
Book Value
$--
EPS
$-2.4
Face value
--
Shares outstanding
11,088,200
CFO
$-282.74 Mln
EBITDA
$-415.20 Mln
Net Profit
$-491.29 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Precision BioSciences (DTIL)
| 29.1 | -4.1 | -2.8 | -59.0 | -50.5 | -53.4 | -- |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
Precision BioSciences (DTIL)
| -64.9 | -69.3 | -83.9 | -11.3 | -40.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Precision BioSciences (DTIL)
|
4.9 | 56.2 | 51.1 | -22.0 | -39.9 | -38.5 | -- | 1.2 |
| 51.0 | 8,079.8 | 1,208.8 | 131.7 | 13.4 | 6.3 | 62.1 | 3.9 | |
| 128.1 | 8,274.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 151.6 | 7,421.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 54.0 | 10,499.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.3 | |
| 41.6 | 11,298.3 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.1 | 5.5 | |
| 302.7 | 8,688.9 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.4 | 14.6 | |
| 26.6 | 10,732.1 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.1 | |
| 125.2 | 12,288.6 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.4 | 4.9 | |
| 284.4 | 12,470.6 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 12.9 | 2.2 |
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform... for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Address: 302 East Pettigrew St., Durham, NC, United States, 27701 Read more
President, CEO & Director
Mr. Michael Amoroso
President, CEO & Director
Mr. Michael Amoroso
Headquarters
Durham, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Precision BioSciences Inc (DTIL) stood at $ 137 Mln as on 31-Mar-25
The share price of Precision BioSciences Inc (DTIL) is $4.92 (NASDAQ) as of 13-Jun-2025 13:25 EDT. Precision BioSciences Inc (DTIL) has given a return of -50.47% in the last 3 years.
Precision BioSciences Inc (DTIL) has a market capitalisation of $ 56 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Precision BioSciences Inc (DTIL) is 1.19 times as on 12-Jun-2025, a 55% discount to its peers’ median range of 2.65 times.
Since, TTM earnings of Precision BioSciences Inc (DTIL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Precision BioSciences Inc (DTIL) and enter the required number of quantities and click on buy to purchase the shares of Precision BioSciences Inc (DTIL).
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Address: 302 East Pettigrew St., Durham, NC, United States, 27701
The CEO & director of Mr. Michael Amoroso. is Precision BioSciences Inc (DTIL), and CFO & Sr. VP is Mr. Michael Amoroso.
There is no promoter pledging in Precision BioSciences Inc (DTIL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Precision BioSciences Inc. (DTIL) | Ratios |
|---|---|
|
Return on equity(%)
|
-38.5
|
|
Operating margin(%)
|
-39.94
|
|
Net Margin(%)
|
-42.99
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Precision BioSciences Inc (DTIL) was $0 Mln.
$-0.11
(
